BARDIAG

BARDiag - Biomarker tests for early cancer detection

Coordinatore	BARD1AG SA    more  Organization address address: RUE DE LA FONTAINE 7 city: GENEVE postcode: 1204 contact info Titolo: Dr. Nome: Christophe Cognome: Bonny Email: send email Telefono: +41 78 723 4330
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	1˙357˙313 €
EC contributo	1˙020˙622 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2010-1
Funding Scheme	BSG-SME
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-12-01   -   2013-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	BARD1AG SA  Organization address address: RUE DE LA FONTAINE 7 city: GENEVE postcode: 1204 contact info Titolo: Dr. Nome: Christophe Cognome: Bonny Email: send email Telefono: +41 78 723 4330	CH (GENEVE)	coordinator	695˙617.60
2	pluriSelect Gmbh  Organization address address: Kreuzstrasse 5 city: Leipzig postcode: 4103 contact info Titolo: Dr. Nome: Jan-Michael Cognome: Heinrich Email: send email Telefono: 493413000000 Fax: 4934130000000	DE (Leipzig)	participant	203˙320.00
3	Genorama OU  Organization address address: Vaksali 17A city: Tartu postcode: 50410 contact info Titolo: Dr. Nome: Indrek Cognome: Kask Email: send email Telefono: +372 5 270307 Fax: +372 7 307298	EE (Tartu)	participant	100˙540.00
4	VIENNALAB DIAGNOSTICS GMBH  Organization address address: Gaudenzdorfer Guertel 43-45 city: VIENNA postcode: 1120 contact info Titolo: Prof. Nome: Andreas Cognome: Kofler Email: send email Telefono: +43 1 8120156 Fax: +43 1 8120156 19	AT (VIENNA)	participant	10˙375.69
5	TARTU ULIKOOL  Organization address address: ULIKOOLI 18 city: TARTU postcode: 50090 contact info Titolo: Dr. Nome: Uri Cognome: Asko Email: send email Telefono: 3725175593 Fax: 3727375275	EE (TARTU)	participant	5˙769.37
6	UNIVERSITAET LEIPZIG  Organization address address: RITTERSTRASSE 26 city: LEIPZIG postcode: 4109 contact info Titolo: Mr. Nome: Gerhard Cognome: Fuchs Email: send email Telefono: +49 341 9735012 Fax: +49 341 9735009	DE (LEIPZIG)	participant	5˙000.00
7	MEDIZINISCHE UNIVERSITAET WIEN  Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Michael Cognome: Gnant Email: send email Telefono: 431404000000 Fax: 431404000000	AT (WIEN)	participant	0.00
8	UNIVERSITE DE GENEVE  Organization address address: Rue du General Dufour 24 city: GENEVE postcode: 1211 contact info Titolo: Dr. Nome: Irmgard Cognome: Irminger-Finger Email: send email Telefono: +41 22 3824327 Fax: +41 22 3791180	CH (GENEVE)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Colorectal cancer and lung cancer cause millions of death each year. Currently there is no suitable non-invasive method for the early detection of these types of cancer. The tumour suppressor gene BARD1 (BRCA1-associated RING domain protein) is aberrantly expressed in several types of cancer and could be a diagnostic target for early cancer diagnosis in blood samples. The overall objective of the project is to develop blood tests for the early detection of colorectal and lung cancer based on cancer-specific BARD1 isoforms. The outlined tests will analyse BARD1 isoforms at two levels: the expression of isoform-specific RNA in circulating tumour cells (CTC) and the presence of isoform-specific autoantibodies in serum. To reach these objectives, several technological challenges have to be overcome. The BARDiag consortium includes 3 SMEs and 4 research centres, who have excellent expertise, specific knowledge, the required lab infrastructure and necessary clinical materials that will enable to conduct this project. Within the frame of the project, innovative methods for the isolation of CTCs in colorectal and lung cancer patients will be developed, the specific signatures of the BARD1 isoforms at both mRNA and autoimmune levels will be defined, and assays for the detection of these isoforms will be established, validated with clinical samples and tested for their marketability. The results of the proposed project will have extensive impacts. Not only more scientific knowledge on the expression of BARD1 isoforms in colorectal and lung cancer will be obtained and therefore the understanding for cancer will be improved, but also non-invasive methods for the early detection of colorectal and lung cancer will be made broadly available in form of commercial test kits. The SMEs will extend their expertise and knowledge and therefore strengthen their economic power, which will contribute to increase European competitiveness.'